Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Their lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.


Biotechnology

Pharmaceutical

Sudo Biosciences

Sudo Biosciences' headquarters in Menlo Park, CA, United States

Scott Byrd

Imran B.

Ian W. Mills

Paul S. Bavier

Fenella Smith

Gordon McMurray

Dan Estes

Dave Johnson

James A. Bristol

Bhaskar Chaudhuri

The Leadership Team at Sudo Biosciences is responsible for setting the strategic direction of the company and overseeing the development of innovative biopharmaceutical therapies. Comprising executives with expertise in clinical operations, finance, manufacturing, and medical development, the team collaborates to ensure the successful advancement of TYK2-targeted programs, driving the company's mission to improve patient outcomes in immune-mediated inflammatory diseases.

Leadership Team

The Operations Team at Sudo Biosciences plays a pivotal role in coordinating and overseeing the development and execution of clinical programs and medicinal chemistry initiatives. Comprised of key leadership positions, including the Chief Business and Financial Officer, Chief Development Officer, and Chief Medical Officer, the team ensures efficient resource allocation and alignment between clinical, financial, and scientific objectives to advance the company’s mission of developing transformative therapies for immune-mediated inflammatory conditions.

Sudo Biosciences

Org chart

Board & advisors

Teams

Leadership Team

Operations Team

Offices

Sudo Biosciences

Org chart

Board & advisors

Teams

Leadership Team

Operations Team

Offices

Related companies